Royalty Pharma plc
General ticker "RPRX" information:
- Sector: Health Care
- Industry: Pharmaceuticals
- Capitalization: $14.2B (TTM average)
Royalty Pharma plc follows the US Stock Market performance with the rate: 41.4%.
Estimated limits based on current volatility of 1.3%: low 39.32$, high 40.32$
Factors to consider:
- Company pays dividends (quarterly): last record date 2025-11-14, amount 0.22$ (Y2.25%)
- Total employees count: 99 as of 2024
- Top business risk factors: Dependence on biopharma sales, Interest rate fluctuations, Government regulations, Market competition, Third-party risks
- Current price 18.6% above estimated high
- Earnings for 9 months up through Q3 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [20.22$, 33.01$]
- 2025-12-31 to 2026-12-31 estimated range: [20.59$, 33.69$]
Financial Metrics affecting the RPRX estimates:
- Positive: with PPE of 6.1 at the end of fiscal year the price was neutral
- Positive: Operating profit margin, % of 57.10 > 18.64
- Positive: Operating cash flow per share per price, % of 24.73 > 13.24
- Negative: negative Industry operating cash flow (median)
- Negative: Investing cash flow per share per price, % of -23.92 <= -14.38
- Negative: -0.15 < Industry inventory ratio change (median), % of 0
- Negative: -0.75 < Inventory ratio change, % of 0
- Positive: 41.86 < Shareholder equity ratio, % of 56.76 <= 63.39
Short-term RPRX quotes
Long-term RPRX plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $2,237.22MM | $2,354.55MM | $2,263.58MM |
| Operating Expenses | $1,930.15MM | $862.40MM | $971.13MM |
| Operating Income | $307.06MM | $1,492.15MM | $1,292.44MM |
| Non-Operating Income | $-77.00MM | $207.94MM | $38.37MM |
| Interest Expense | $187.96MM | $187.19MM | $225.51MM |
| R&D Expense | $177.11MM | $52.00MM | $2.00MM |
| Income(Loss) | $230.06MM | $1,700.09MM | $1,330.81MM |
| Profit(Loss)* | $42.83MM | $1,134.83MM | $858.98MM |
| Stockholders Equity | $9,525.37MM | $10,084.29MM | $10,342.37MM |
| Assets | $16,813.47MM | $16,381.85MM | $18,222.72MM |
| Operating Cash Flow | $2,143.98MM | $2,987.80MM | $2,768.99MM |
| Investing Cash Flow | $-1,029.42MM | $-2,072.79MM | $-2,678.11MM |
| Financing Cash Flow | $-944.86MM | $-2,148.75MM | $361.14MM |
| Earnings Per Share** | $0.10 | $2.54 | $1.93 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.